Publications by authors named "T H Roels"
Objectives: In addition to bone fragility, patients with osteogenesis imperfecta (OI) type III have typical craniofacial abnormalities, such as a triangular face and maxillary micrognathism. However, in the osteogenesis imperfecta mouse (oim), a validated model of OI type III, few descriptions exist of craniofacial phenotype. Treatment of OI mostly consists of bisphosphonate administration.
View Article and Find Full Text PDFBeginning in March 2020, to reduce COVID-19 transmission, the US President's Emergency Plan for AIDS Relief supporting voluntary medical male circumcision (VMMC) services was delayed in 15 sub-Saharan African countries. We reviewed performance indicators to compare the number of VMMCs performed in 2020 with those performed in previous years. In all countries, the annual number of VMMCs performed decreased 32.
View Article and Find Full Text PDFArticle Synopsis
- Osteogenesis imperfecta (OI) is caused by collagen type 1 gene mutations, leading to low bone density and fragility, with reported gender differences in patients that lack consistent data.
- A study previously showed that the sclerostin antibody (Scl-Ab) improved bone parameters in female oim/oim mice, and this research aimed to investigate its effects on male oim/oim mice.
- Results indicated that while Scl-Ab enhanced bone density and structure in both male and female mice, male oim/oim had lower bone mineral content and more fractures than females, but Scl-Ab treatment helped improve their bone thickness and decrease fracture rates.
Objective: To investigate the role of Spam1 hyaluronidase in age-related bone and cartilage changes in the mouse knee.
Design: Spam1 and WT mice were euthanised at different ages from 10 to 52 weeks. The right hindlimbs were dissected, scanned with peripheral Quantitative Computed Tomography (pQCT) and then decalcified for histological analysis (modified Mankin score).
In osteogenesis imperfecta (OI), vertebrae brittleness causes thorax deformations and leads to cardiopulmonary failure. As sclerostin-neutralizing antibodies increase bone mass and strength in animal models of osteoporosis, their administration in two murine models of severe OI enhanced the strength of vertebrae in growing female Crtap mice but not in growing male Col1a1 mice. However, these two studies ignored the impact of antibodies on spine growth, fracture rates, and compressive mechanical properties.
View Article and Find Full Text PDF